Clinical trial · Interventional
Generative AI Patient Education Module for Breast Oncology
Accuracy and Effect of Prescribed Generative AI Patient Education Module Within Breast Oncology Care
NCT07512271CI-TRIAL-00120891recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the University of California, San Francisco breast cancer center and affiliate sites.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Carcinoma of the Breast | Breast Carcinoma | ALIAS | 0.90 |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OpenEvidence CareConnect | Other | — | UNRESOLVED |
| Survey (Participant) | Other | — | UNRESOLVED |
| Survey (Provider) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Safety Lead-in Phase
- description
- Participants will receive access to OpenEvidence CareConnect a Retrieval-Augmented Generation (RAG) Large Language Model (LLM) tool that provides general health and breast cancer-specific information for 3 months.
- interventionNames
- Other: Survey (Participant)
- Other: OpenEvidence CareConnect
- Other: Survey (Provider)
- type
- EXPERIMENTAL
- label
- Interventional (Immediate Access)
- description
- Participants will be given immediate access to OpenEvidence CareConnect for up to 3 months and complete surveys regarding use of tool. Participants are then followed up for an additional 3 months.
- interventionNames
- Other: Survey (Participant)
- Other: OpenEvidence CareConnect
- Other: Survey (Provider)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Females or males ages 18 and over. 2. Patients must have either: 1. Stage IV breast cancer facing a treatment change and are expected to have follow-up visits at least once every three months, or 2. Stage I-III breast cancer diagnosed within the past 6 months. 3. Basic computer literacy and regular internet access at home. 4. Able to understand study procedures and to comply with them for the entire length of the study. 5. Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Contraindication to any study-related procedure or assessment. 2. Cognitive impairment that would interfere with tool usage or survey completion
References
Publications (0)
Data not yet available
No reference posted for this study.